Real World Evidence on the Impact of Early and Appropriate Use of Aztreonam-Avibactam (ATM-AVI)
Real World Evidence on the Impact of Early and Appropriate Use of Aztreonam-Avibactam (ATM-AVI) supports researchers studying diagnostic-guided treatment of resistant infections to assess timeliness and effectiveness.
Funder: Pfizer Inc.
Due Dates: November 25, 2026 (Submission) | February 17, 2027 (Anticipated notification) | June 1, 2027 (IRB approval, or project start) | June 2027 (Anticipated start) | December 2028 (Anticipated end)
Funding Amounts: Up to $50,000 USD per project for up to 18 months; $100,000 total for 2–3 awards
Summary: Supports real-world research on diagnostic-guided, early and appropriate ATM-AVI treatment in adults with resistant infections.
Key Information: Both the institution and PI must be based in Brazil, Chile, India, Italy, South Africa, Spain, or the United Kingdom.
Description
Pfizer’s competitive research program supports independent studies assessing how diagnostic workflows enable earlier selection of appropriate aztreonam-avibactam (ATM-AVI) therapy in real-world clinical settings. Research must focus on adults with suspected or documented infections caused by carbapenem-resistant Enterobacterales (CRE) or Stenotrophomonas maltophilia, with treatment decisions guided by actionable rapid diagnostic results.
Studies must assess time to appropriate therapy and clinical effectiveness with ATM-AVI. Measurement of diagnostic-guided antibiotic escalation and de-escalation, along with microbiological outcomes, is strongly encouraged. Health economic outcomes may be included as an additional component. Pfizer reviews applications and makes final funding decisions; grantees retain responsibility for the design, implementation, sponsorship, and conduct of the independent research.
